Fecal Microbiota Transplantation for Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess Fecal Microbiota Transplantation (FMT) efficacy in improving Parkinson’s disease (PD) symptoms. Background: Dysregulation of the microbiome–gut–brain axis is a key pathophysiological mechanism…Modulation of working memory in prodromal DLB by non-invasive brain stimulation of the striatum and cerebellum
Objective: We aimed to modulate working memory (WM) in patients with MCI with Lewy bodies (MCI-LB) by non-invasive stimulation of the striatum with or without…Repeated Scanning Ultrasound in an Alpha-synuclein Preformed Fibril model
Objective: To investigate the therapeutic potential of repeated scanning ultrasound (SUS)-mediated blood-brain barrier (BBB) opening in a mouse model of Parkinson’s disease (PD). Background: PD…Impact of Gastrointestinal Dysfunction Symptoms on Psychomotor Recovery Following 8-Week Aerobic Interval Training in Parkinson’s Disease – Preliminary Results
Objective: To investigate the impact of gastrointestinal dysfunction symptoms (GIDS) on psychomotor recovery following 8-week aerobic interval training (AIT) in Parkinson's disease (PD). Background: GIDS…Honey products in Parkinson’s disease – randomized placebo-controlled double-blind pilot study
Objective: The purpose of this study is to examine whether consumption of honey products can improve symptoms and their diurnal fluctuations in patients with Parkinson's…Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease
Objective: The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics (PK), food-effect and pharmacodynamics of VENT-02 in healthy volunteers Background: Vent-02…Retention & Safety in a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo (TOPAZ) in Persons with Neurodegenerative Parkinsonism (NDP)
Objective: To assess retention and safety in the ongoing TOPAZ trial, NCT03924414 Background: People with NDP face a four-fold increased fracture risk, yet preventive treatment…A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment
Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism
Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »